Myasthenia Gravis: The 'No Paralyzer' Plan

If you're like me, myasthenia gravis patients make you question every dose you're calculating. The acetylcholine receptor deficiency at the neuromuscular junction creates a fundamentally different pharmacology than any other patient — they're resistant to depolarizing blockers, exquisitely sensitive to non-depolarizing blockers, and at high risk for post-operative respiratory failure even with a "normal" reversal. On the anesthesiology oral boards, myasthenia gravis tests whether you understand the underlying physiology well enough to build a safe anesthetic from first principles.

The most common surgical context for myasthenia on the boards is thymectomy — because 15% of MG patients have a thymoma, and removal can be curative. It's also a thoracic case with post-operative respiratory implications, which gives the examiners multiple angles to probe your management.

The Core Logic

Myasthenia gravis is an autoimmune disease — antibodies (usually anti-AChR) block and destroy postsynaptic acetylcholine receptors at the neuromuscular junction. The result: reduced receptor availability and impaired neuromuscular transmission. Clinically, this manifests as fatigable weakness — worse with exertion, better with rest.

The anesthetic implications follow directly: succinylcholine requires more drug to achieve depolarization (resistance) because there are fewer receptors to stimulate. Non-depolarizing blockers (rocuronium, vecuronium) require dramatically less drug because the baseline receptor availability is already reduced — tiny doses produce prolonged, profound blockade. Any residual NMB in the post-operative period is catastrophic in a patient who is already operating at the edge of their respiratory reserve.

How the Examiner Tests This

Standard scenario: a 45-year-old woman with myasthenia gravis and a thymoma is scheduled for video-assisted thoracoscopic thymectomy. "How do you plan to manage this patient's neuromuscular blockade?" The answer should start with: I will avoid NMBs entirely if possible.

Key probes: "The surgeon says they need a completely still field — can you give rocuronium?" If you must use an NMB, use the smallest effective dose with quantitative TOF monitoring, and have Sugammadex immediately available. "Why not neostigmine for reversal?" Neostigmine is an acetylcholinesterase inhibitor — it increases acetylcholine at all cholinergic synapses, not just the NMJ. In an MG patient on pyridostigmine (the same class), this can precipitate cholinergic crisis: excess muscarinic stimulation causing bradycardia, hypersalivation, bronchospasm, and worsening weakness. Sugammadex bypasses this entirely.

The Board Trap

The NMB dose trap: giving "standard" doses of rocuronium. A patient without MG receives 0.6-1.2 mg/kg for intubating conditions. An MG patient may need 20-30% of that dose for the same effect, and the duration will be unpredictably prolonged. Start low, monitor quantitatively, and have Sugammadex available in the correct dose for full reversal.

The pyridostigmine trap: forgetting to continue the patient's pyridostigmine perioperatively. Stopping the acetylcholinesterase inhibitor perioperatively causes sudden worsening of myasthenic weakness — exactly what you're trying to avoid. Continue the drug as close to surgery time as possible and restart it as soon as the patient can swallow. If the patient is NPO for an extended period post-operatively, discuss IV pyridostigmine or alternative management with neurology.

Lead-In Phrases

• "My plan for this myasthenia gravis patient is TIVA without neuromuscular blocking agents — propofol and remifentanil provide excellent conditions for thymectomy without exposing the patient to the risks of prolonged NMB."
• "If NMB is required, I will use the smallest possible dose of rocuronium — starting at 0.1-0.2 mg/kg — with quantitative TOF monitoring throughout the case."
• "I will reverse with Sugammadex rather than neostigmine — neostigmine can precipitate a cholinergic crisis in a patient already taking an acetylcholinesterase inhibitor, and Sugammadex provides complete, predictable reversal."
• "I will continue the patient's pyridostigmine perioperatively and plan post-operative admission to a monitored setting — these patients are at high risk for post-operative myasthenic crisis and respiratory failure."
• "My extubation criteria are more stringent than standard: I need a TOF ratio above 0.9, sustained head lift for 5 seconds, adequate tidal volume, and a comfortable patient before I extubate."

FAQs

What is a myasthenic crisis and how do I manage it?

Myasthenic crisis is an acute worsening of weakness severe enough to cause respiratory failure — either from the disease itself (triggered by infection, surgery, medications, or stopping pyridostigmine) or from inadequate treatment. Management: support ventilation with intubation, continue or restart pyridostigmine, and consider plasma exchange or IVIG to reduce the antibody burden. This is a neurology ICU issue — I will notify neurology immediately.

What about the cholinergic crisis — how do I distinguish it from myasthenic crisis?

Both present with weakness. Key differentiators: cholinergic crisis is associated with excessive secretions, miosis, bradycardia, and fasciculations — signs of muscarinic excess. It occurs from too much acetylcholinesterase inhibitor, not too little. If in doubt, the edrophonium (Tensilon) test can help: improvement with edrophonium suggests myasthenic crisis; worsening suggests cholinergic. But on the boards, the context usually makes this clear.

Are there specific drugs that worsen myasthenia I should avoid?

Yes — aminoglycoside antibiotics, fluoroquinolones, magnesium, beta-blockers, and calcium channel blockers can all impair neuromuscular transmission and worsen myasthenic weakness. Magnesium is particularly relevant in OB — a myasthenic patient who receives magnesium for preeclampsia can develop profound weakness and respiratory failure. This drug interaction is a favorite board probe.

Myasthenia anesthesia is about knowing the sensitivity difference and planning around it. No paralytics unless necessary, smallest possible dose, quantitative monitoring, Sugammadex for reversal. Practice the thymectomy scenario in Boards Bot until the TIVA-plus-Sugammadex answer is your automatic default for any MG patient.